The University of Alabama at Birmingham announced that it will take part in an NIH-sponsored global clinical trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adult patients diagnosed with COVID-19.
The drug remdesivir will be the first agent evaluated in the trial.
The UAB site was activated on Wednesday by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. That means it can begin enrollment as part of this phase three therapeutic clinical trial immediately.
